Precision Oncology Entrepreneur, CEO Misvik Biology Ltd, Target Identification Lead, Orion Pharma Oncology
Turku, Suomi
Joined April 2020
- Tweets23
- Following98
- Followers19
- Likes2.7K
Juha K Rantala retweeted
The moment! The noise! The crowd!
Finland are in Malaga to stay 🇫🇮
#DavisCupFinals | @tennisfi | @EmilRuusuvuori
Juha K Rantala retweeted
Congratulations Ivaska Lab! What a great honor for us to contribute to this elegant piece of science! The cell microarray technologies still got it😃 Interested to develop your custom microarray platform? Contact us for more info! pnas.org/doi/10.1073/pnas.23… @IvaskaLab @PNASNews
Juha K Rantala retweeted
Target discovery using RNAi screening is still a valid approach. This time a novel DDR target FBXL12 for cancer therapy. Congratulations Sangfelt Lab! sciencedirect.com/science/ar…
Juha K Rantala retweeted
Last Call! Calling all early career researchers interested on nanomedicine and looking for a PhD position. Application period to @MelomanesMSCA training network is closing! #PhD melomanes.eu/recruitment/
Juha K Rantala retweeted
Huge congratulations to our newest Dr, Dr Patyra🎩🏆 Next three on the line😀 Go team Misvik! @MisvikB
Juha K Rantala retweeted
Interested in tailor made peptidyl diphenyl phosphonate warheads for analysis of proteolytic networks? Check out our latest collaborative study in Nature Chemical Biology: nature.com/articles/s41589-0…
Juha K Rantala retweeted
Amazing news!! European Commission awards 20M€ for the H2020 Research and Innovation project PrecisionTox to develop New Approach Methodologies for Chemical Safety to transform environmental health protection! Congratulations to the whole consortium! #PrecisionTox #misvikbiology
Juha K Rantala retweeted
We've partnered with @CRUKresearch to deliver a series of free, online Entrepreneurial Training Seminars. This 3-part series, featuring @ttp_plc & @VennerShipley, aims to support the development of viable #startups that will address unmet medical needs: bit.ly/3in1AcH
Juha K Rantala retweeted
For rare cancers, n-of-1 style studies may be the only approach to demonstrate novel therapies. Study our latest case report of ex vivo modelling of drug efficacy in an extreme rare epithelial-myoepithelial salivary gland cancer: sciencedirect.com/science/ar…
Juha K Rantala retweeted
Fresh from the press! Parallel ex vivo modelling of therapy efficacy on tumor and malignant ascites in rare Krukenberg tumor identifies VEGFR-TKI mediated targeting of immunosuppressive tumor associated macrophages.
sciencerepository.org/ex-viv…
@MisvikB #misvikbiology @Cancer_IO_
Juha K Rantala retweeted
Ex vivo drug screen and the world’s first established urachal cancer cell line descibed in our latest paper published today in BMC Cancer: bmccancer.biomedcentral.com/… @BMC_series, @MisvikB
